3.53
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 3.58 0.05 +1.42%
loading
Precedente Chiudi:
$3.53
Aprire:
$3.52
Volume 24 ore:
215.87K
Relative Volume:
0.52
Capitalizzazione di mercato:
$35.67M
Reddito:
-
Utile/perdita netta:
$-23.87M
Rapporto P/E:
-0.1795
EPS:
-19.67
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
-1.40%
1M Prestazione:
+26.07%
6M Prestazione:
+16.12%
1 anno Prestazione:
-16.75%
Intervallo 1D:
Value
$3.42
$3.58
Intervallo di 1 settimana:
Value
$3.42
$3.74
Portata 52W:
Value
$2.30
$4.42

Polypid Ltd Stock (PYPD) Company Profile

Name
Nome
Polypid Ltd
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
61
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-13
Name
Ultimi documenti SEC
Name
PYPD's Discussions on Twitter

Confronta PYPD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PYPD
Polypid Ltd
3.53 35.67M 0 -23.87M -47.63M -19.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Polypid Ltd Stock (PYPD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-05 Iniziato Roth Capital Buy
2025-06-02 Ripresa H.C. Wainwright Buy
2025-01-28 Iniziato Rodman & Renshaw Buy
2021-09-14 Iniziato JMP Securities Mkt Outperform
2021-07-30 Iniziato Cantor Fitzgerald Overweight
2020-11-24 Aggiornamento Raymond James Outperform → Strong Buy
2020-08-10 Iniziato Alliance Global Partners Buy
2020-07-21 Iniziato BMO Capital Markets Outperform
2020-07-21 Iniziato Barclays Overweight
2020-07-21 Iniziato Raymond James Outperform
Mostra tutto

Polypid Ltd Borsa (PYPD) Ultime notizie

pulisher
Jun 18, 2025

Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid stock price target lowered to $14 at JMP on warrant dilution - Investing.com Australia

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Citizens JMP Adjusts Price Target for PolyPid (PYPD) Amid Warrant Developments | PYPD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo

Jun 11, 2025
pulisher
Jun 11, 2025

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed - insights.citeline.com

Jun 11, 2025
pulisher
Jun 10, 2025

HC Wainwright Issues Positive Forecast for PolyPid (NASDAQ:PYPD) Stock Price - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

PolyPid reports positive phase 3 surgical infection drug trial - גלובס

Jun 10, 2025
pulisher
Jun 09, 2025

PolyPid (PYPD) Target Price Increased as Phase 3 Trial Data Impr - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid shares surge on successful D-PLEX100 trial results By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid shares surge on successful D-PLEX100 trial results - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : PolyPid Ltd.Special Call - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid (PYPD) Reports Positive Phase 3 Trial Results for D-PLEX100 | PYPD Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

What is Roth Capital’s Forecast for PolyPid Q2 Earnings? - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Roth Capital Begins Coverage on PolyPid (NASDAQ:PYPD) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100 - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Major Clinical Trial Results: PolyPid's D-PLEX100 Shows New Data for Preventing Post-Surgery Infections - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rat - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rating | PYPD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates PolyPid at Buy With $9 Price Target - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

PolyPid initiated with a Buy at Roth Capital - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

What is HC Wainwright’s Forecast for PolyPid Q2 Earnings? - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

FY2027 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

PolyPid (NASDAQ:PYPD) Now Covered by HC Wainwright - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout - newsblaze.com

Jun 02, 2025
pulisher
Jun 02, 2025

PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright assumes coverage on PolyPid stock with buy rating - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

PolyPid assumed with a Buy at H.C. Wainwright - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright assumes coverage on PolyPid stock with buy rating By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

PolyPid (PYPD) Receives a 'Buy' Rating from HC Wainwright & Co. - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright Initiates Buy Coverage on PolyPid (PYPD) with $1 - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 30, 2025

PolyPid Expands Share Option Plan to Boost Stakeholder Engagement - TipRanks

May 30, 2025

Polypid Ltd Azioni (PYPD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):